Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis

Cerivastatin, an HMG-CoA reductase inhibitor withdrawn from the market due to serious adverse effects, is metabolized primarily by CYP2C8. The occurrence of associated myotoxicity and rhabdomyolysis were attributed to altered cerivastatin pharmacokinetics due to gemfibrozil-inhibition or genetic var...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Kaspera, Rüdiger, Naraharisetti, Suresh B., Tamraz, Bani, Sahele, Tariku, Cheesman, Matthew J., Kwok, Pui-Yan, Marciante, Kristin, Heckbert, Susan R., Psaty, Bruce M., Totah, Rheem A.
Format: Artigo
Jezik:Inglês
Izdano: 2010
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2993694/
https://ncbi.nlm.nih.gov/pubmed/20739906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FPC.0b013e32833ecace
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items